Edgewise Therapeutics (EWTX)
Edgewise Therapeutics on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, financials, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
11.8M
Short interest
settlement 2026-10-15
8.5
Days to cover
+2.9 days vs prior
57.4%
Short share of volume
2026-11-02
226
Fails to deliver
settlement 2026-09-09
Thu 5 Nov
Next earnings
estimated date
-$1.9M
Insider flow, 90 days
0 buys, 19 sells
As of 2026-11-02.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in EWTX is 11,751,785 shares, up 2,207,942 shares over the last month. Over the last 48 readings it ranged from 5,642,454 shares (13 December 2024) to 14,306,872 shares (30 May 2025). At the reported average volume of 1.4M shares a day that is 8.5 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/ewtx" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 11,751,785 | +4.7% | 1,385,615 | 8.48 |
| 2026-09-30 | 11,224,347 | +17.6% | 2,003,524 | 5.60 |
| 2026-09-15 | 9,543,843 | +2.1% | 1,188,397 | 8.03 |
| 2026-08-31 | 9,346,141 | -3.4% | 1,164,287 | 8.03 |
| 2026-08-14 | 9,675,389 | -1.6% | 1,513,577 | 6.39 |
| 2026-07-31 | 9,835,054 | -2.4% | 815,024 | 12.07 |
| 2026-07-15 | 10,074,332 | -4.0% | 1,211,852 | 8.31 |
| 2026-06-30 | 10,492,798 | +5.7% | 2,083,624 | 5.04 |
| 2026-06-15 | 9,931,057 | -9.0% | 1,739,288 | 5.71 |
| 2026-05-29 | 10,911,621 | +5.4% | 982,747 | 11.10 |
| 2026-05-15 | 10,353,369 | +2.2% | 1,483,537 | 6.98 |
| 2026-04-30 | 10,134,013 | +0.6% | 1,084,798 | 9.34 |
| 2026-04-15 | 10,076,470 | +6.7% | 861,612 | 11.69 |
| 2026-03-31 | 9,448,351 | -0.3% | 798,949 | 11.83 |
| 2026-03-13 | 9,475,471 | -0.1% | 957,936 | 9.89 |
| 2026-02-27 | 9,484,539 | -0.1% | 756,443 | 12.54 |
| 2026-02-13 | 9,492,160 | +0.0% | 816,213 | 11.63 |
| 2026-01-30 | 9,488,947 | +0.8% | 1,197,198 | 7.93 |
| 2026-01-15 | 9,417,968 | -19.4% | 1,087,230 | 8.66 |
| 2025-12-31 | 11,687,594 | +11.1% | 2,360,820 | 4.95 |
| 2025-12-15 | 10,522,544 | -5.6% | 1,458,735 | 7.21 |
| 2025-11-28 | 11,148,309 | +11.0% | 1,158,376 | 9.62 |
| 2025-11-14 | 10,045,672 | +5.7% | 1,392,333 | 7.21 |
| 2025-10-31 | 9,506,297 | +10.3% | 848,153 | 11.21 |
| 2025-10-15 | 8,616,447 | +17.9% | 796,820 | 10.81 |
| 2025-09-30 | 7,306,230 | -14.8% | 1,162,443 | 6.29 |
| 2025-09-15 | 8,569,893 | -15.1% | 818,051 | 10.48 |
| 2025-08-29 | 10,094,026 | -1.2% | 793,676 | 12.72 |
| 2025-08-15 | 10,215,170 | +0.2% | 657,911 | 15.53 |
| 2025-07-31 | 10,192,737 | -8.0% | 570,751 | 17.86 |
| 2025-07-15 | 11,074,084 | -12.5% | 587,050 | 18.86 |
| 2025-06-30 | 12,657,398 | +1.0% | 935,214 | 13.53 |
| 2025-06-13 | 12,531,401 | -12.4% | 1,047,469 | 11.96 |
| 2025-05-30 | 14,306,872 | +12.9% | 999,834 | 14.31 |
| 2025-05-15 | 12,677,158 | -4.4% | 1,130,325 | 11.22 |
| 2025-04-30 | 13,258,045 | +3.2% | 1,052,525 | 12.60 |
| 2025-04-15 | 12,850,577 | +23.7% | 4,202,654 | 3.06 |
| 2025-03-31 | 10,387,232 | +14.3% | 1,444,211 | 7.19 |
| 2025-03-14 | 9,088,389 | +4.1% | 1,551,233 | 5.86 |
| 2025-02-28 | 8,732,881 | +8.4% | 1,117,912 | 7.81 |
| 2025-02-14 | 8,057,846 | +14.2% | 940,526 | 8.57 |
| 2025-01-31 | 7,055,664 | +4.7% | 866,242 | 8.15 |
| 2025-01-15 | 6,736,305 | +9.7% | 1,006,915 | 6.69 |
| 2024-12-31 | 6,141,675 | +8.8% | 1,088,980 | 5.64 |
| 2024-12-13 | 5,642,454 | -1.8% | 710,901 | 7.94 |
| 2024-11-29 | 5,742,967 | -10.2% | 469,305 | 12.24 |
| 2024-11-15 | 6,391,944 | -12.3% | 798,555 | 8.00 |
| 2024-10-31 | 7,289,836 | -14.1% | 777,918 | 9.37 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 2 November 2026, the short share of EWTX volume is 57.4%, down 0.7 points over the last five sessions. Over the last 30 readings it ranged from 21.0% (27 October 2026) to 78.1% (9 October 2026). The latest reading is 3.9 points above the 30-session average of 53.5%, on 345K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-02 | 198K | 345K | 57.4% | 0 |
| 2026-10-30 | 182K | 365K | 49.7% | 0 |
| 2026-10-29 | 218K | 508K | 42.9% | 0 |
| 2026-10-28 | 602K | 815K | 73.9% | 0 |
| 2026-10-27 | 53K | 254K | 21.0% | 0 |
| 2026-10-26 | 81K | 140K | 58.1% | 0 |
| 2026-10-23 | 98K | 158K | 62.1% | 0 |
| 2026-10-22 | 160K | 239K | 67.0% | 0 |
| 2026-10-21 | 466K | 622K | 74.9% | 658 |
| 2026-10-20 | 441K | 706K | 62.4% | 392 |
| 2026-10-19 | 146K | 667K | 21.9% | 6,093 |
| 2026-10-16 | 206K | 443K | 46.5% | 0 |
| 2026-10-15 | 497K | 698K | 71.1% | 107 |
| 2026-10-14 | 333K | 526K | 63.4% | 0 |
| 2026-10-13 | 169K | 288K | 58.6% | 204 |
| 2026-10-12 | 117K | 252K | 46.3% | 213 |
| 2026-10-09 | 242K | 310K | 78.1% | 157 |
| 2026-10-08 | 283K | 511K | 55.4% | 202 |
| 2026-10-07 | 170K | 598K | 28.4% | 238 |
| 2026-10-06 | 237K | 440K | 53.9% | 141 |
| 2026-10-05 | 329K | 737K | 44.5% | 0 |
| 2026-10-02 | 221K | 472K | 46.9% | 0 |
| 2026-10-01 | 207K | 406K | 51.0% | 312 |
| 2026-09-30 | 251K | 576K | 43.5% | 553 |
| 2026-09-29 | 186K | 358K | 52.0% | 0 |
| 2026-09-28 | 588K | 912K | 64.5% | 0 |
| 2026-09-25 | 416K | 664K | 62.6% | 0 |
| 2026-09-24 | 229K | 449K | 50.9% | 2,338 |
| 2026-09-23 | 581K | 1.3M | 46.5% | 3,809 |
| 2026-09-22 | 507K | 1.0M | 49.8% | 27,304 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 9 September 2026, the fails-to-deliver balance in EWTX is 226 shares, down 16,774 shares over the last settlement date. Over the last 30 readings it ranged from 1 share (30 June 2026) to 203,591 shares (16 January 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-09-09 | 226 | $43.82 | $10K |
| 2026-08-31 | 17,000 | $42.76 | $727K |
| 2026-08-12 | 911 | $44.31 | $40K |
| 2026-08-07 | 342 | $44.42 | $15K |
| 2026-07-31 | 2,807 | $41.12 | $115K |
| 2026-07-29 | 1,026 | $40.35 | $41K |
| 2026-07-21 | 321 | $38.81 | $12K |
| 2026-07-20 | 100 | $39.76 | $4K |
| 2026-07-10 | 13,661 | $48.35 | $661K |
| 2026-07-08 | 35,390 | $43.13 | $1.5M |
| 2026-07-07 | 14 | $40.10 | $561 |
| 2026-06-30 | 1 | $40.92 | $41 |
| 2026-06-15 | 2,848 | $34.83 | $99K |
| 2026-06-01 | 22,569 | $34.16 | $771K |
| 2026-05-15 | 168 | $34.01 | $6K |
| 2026-05-13 | 9,067 | $34.01 | $308K |
| 2026-04-21 | 5,540 | $33.97 | $188K |
| 2026-04-15 | 9 | $33.16 | $298 |
| 2026-04-06 | 37,906 | $33.33 | $1.3M |
| 2026-03-24 | 28 | $29.80 | $834 |
| 2026-03-13 | 5 | $29.94 | $150 |
| 2026-03-12 | 58 | $30.99 | $2K |
| 2026-03-05 | 1,333 | $28.88 | $38K |
| 2026-02-25 | 731 | $30.91 | $23K |
| 2026-02-17 | 2 | $30.01 | $60 |
| 2026-02-05 | 1,493 | $28.47 | $43K |
| 2026-01-30 | 257 | $28.78 | $7K |
| 2026-01-22 | 144 | $29.24 | $4K |
| 2026-01-20 | 8,000 | $27.39 | $219K |
| 2026-01-16 | 203,591 | $26.60 | $5.4M |
Insider trades
SEC Form 4, newest first. JSONInsiders at EWTX reported 19 open-market sells worth $1.9M in the last 90 days and no open-market buys. Latest filing: Fox Jonathan C (Director) on 2026-10-01.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-10-01 | Fox Jonathan C | Director | Grant | 308 | $0.00 | $0 | 25K |
| 2026-08-13 | Donovan Joanne M. | CMO | Sell | 3K | $43.41 | $127K | 9K |
| 2026-08-12 | Russell Alan J | Chief Scientific Officer | Sell | 390 | $44.46 | $17K | 31K |
| 2026-08-12 | Russell Alan J | Chief Scientific Officer | Sell | 2K | $43.68 | $99K | 32K |
| 2026-08-12 | Russell Alan J | Chief Scientific Officer | Sell | 3K | $43.68 | $141K | 34K |
| 2026-08-12 | Russell Alan J | Chief Scientific Officer | Exercise or conversion | 7K | $0.00 | $0 | 37K |
| 2026-08-12 | Russell Alan J | Chief Scientific Officer | Exercise or conversion | 6K | $0.00 | $0 | 30K |
| 2026-08-12 | MOORE JOHN R | General Counsel | Sell | 2K | $43.80 | $106K | 18K |
| 2026-08-12 | MOORE JOHN R | General Counsel | Sell | 99 | $44.50 | $4K | 20K |
| 2026-08-12 | MOORE JOHN R | General Counsel | Sell | 59 | $44.41 | $3K | 20K |
| 2026-08-12 | MOORE JOHN R | General Counsel | Sell | 2K | $43.81 | $107K | 20K |
| 2026-08-12 | MOORE JOHN R | General Counsel | Exercise or conversion | 7K | $0.00 | $0 | 23K |
| 2026-08-12 | MOORE JOHN R | General Counsel | Exercise or conversion | 6K | $0.00 | $0 | 16K |
| 2026-08-12 | KOCH KEVIN | President and CEO | Sell | 913 | $44.33 | $40K | 52K |
| 2026-08-12 | KOCH KEVIN | President and CEO | Sell | 8K | $43.66 | $361K | 53K |
| 2026-08-12 | KOCH KEVIN | President and CEO | Sell | 9K | $43.64 | $383K | 62K |
| 2026-08-12 | KOCH KEVIN | President and CEO | Exercise or conversion | 22K | $0.00 | $0 | 70K |
| 2026-08-12 | KOCH KEVIN | President and CEO | Exercise or conversion | 18K | $0.00 | $0 | 49K |
| 2026-08-12 | Donovan Joanne M. | CMO | Sell | 800 | $44.52 | $36K | 12K |
| 2026-08-12 | Donovan Joanne M. | CMO | Sell | 104 | $44.43 | $5K | 12K |
| 2026-08-12 | Donovan Joanne M. | CMO | Sell | 3K | $43.71 | $121K | 12K |
| 2026-08-12 | Donovan Joanne M. | CMO | Sell | 3K | $43.78 | $124K | 15K |
| 2026-08-12 | Donovan Joanne M. | CMO | Exercise or conversion | 7K | $0.00 | $0 | 18K |
| 2026-08-12 | Donovan Joanne M. | CMO | Exercise or conversion | 6K | $0.00 | $0 | 11K |
| 2026-08-12 | Derakhshan Behrad | Chief Business Officer | Sell | 2K | $43.70 | $108K | 32K |
| 2026-08-12 | Derakhshan Behrad | Chief Business Officer | Sell | 150 | $44.44 | $7K | 34K |
| 2026-08-12 | Derakhshan Behrad | Chief Business Officer | Sell | 304 | $44.50 | $14K | 34K |
| 2026-08-12 | Derakhshan Behrad | Chief Business Officer | Sell | 2K | $43.79 | $95K | 35K |
| 2026-08-12 | Derakhshan Behrad | Chief Business Officer | Exercise or conversion | 8K | $0.00 | $0 | 37K |
| 2026-08-12 | Derakhshan Behrad | Chief Business Officer | Exercise or conversion | 6K | $0.00 | $0 | 29K |
| 2026-07-01 | Fox Jonathan C | Director | Grant | 319 | $0.00 | $0 | 25K |
| 2026-07-01 | Russell Alan J | Chief Scientific Officer | Sell | 70K | $0.39 | $27K | 25K |
| 2026-07-01 | Russell Alan J | Chief Scientific Officer | Sell | 130K | $0.39 | $51K | 94K |
| 2026-07-01 | Russell Alan J | Chief Scientific Officer | Exercise or conversion | 70K | $0.18 | $13K | 225K |
| 2026-07-01 | Russell Alan J | Chief Scientific Officer | Exercise or conversion | 130K | $0.45 | $59K | 155K |
| 2026-05-05 | Donovan Joanne M. | CMO | Sell | 50K | $38.57 | $1.9M | 4K |
| 2026-05-05 | Donovan Joanne M. | CMO | Exercise or conversion | 50K | $7.08 | $354K | 54K |
| 2026-05-04 | Donovan Joanne M. | CMO | Sell | 5K | $31.29 | $164K | 4K |
| 2026-04-01 | Donovan Joanne M. | CMO | Sell | 29K | $32.31 | $926K | 10K |
| 2026-04-01 | Donovan Joanne M. | CMO | Exercise or conversion | 29K | $7.08 | $203K | 38K |
| 2026-04-01 | Fox Jonathan C | Director | Grant | 339 | $0.00 | $0 | 25K |
| 2026-03-31 | Donovan Joanne M. | CMO | Sell | 21K | $32.12 | $685K | 10K |
| 2026-03-31 | Donovan Joanne M. | CMO | Exercise or conversion | 21K | $7.08 | $151K | 31K |
| 2026-03-27 | Donovan Joanne M. | CMO | Sell | 7K | $30.98 | $209K | 10K |
| 2026-03-27 | Donovan Joanne M. | CMO | Sell | 10K | $30.98 | $298K | 16K |
| 2026-01-21 | Edris Badreddin | Director | Sell | 66K | $29.44 | $2.0M | 20K |
| 2026-01-21 | Edris Badreddin | Director | Sell | 10K | $29.44 | $308K | 86K |
| 2026-01-21 | Edris Badreddin | Director | Sell | 8K | $29.44 | $224K | 97K |
| 2026-01-21 | Edris Badreddin | Director | Sell | 17K | $29.44 | $507K | 104K |
| 2026-01-21 | Edris Badreddin | Director | Sell | 14K | $29.44 | $403K | 122K |
| 2026-01-21 | Edris Badreddin | Director | Exercise or conversion | 8K | $0.71 | $5K | 135K |
| 2026-01-21 | Edris Badreddin | Director | Exercise or conversion | 66K | $1.93 | $128K | 128K |
| 2026-01-21 | Edris Badreddin | Director | Exercise or conversion | 10K | $1.93 | $20K | 61K |
| 2026-01-21 | Edris Badreddin | Director | Exercise or conversion | 17K | $0.64 | $11K | 51K |
| 2026-01-21 | Edris Badreddin | Director | Exercise or conversion | 14K | $0.39 | $5K | 34K |
| 2026-01-02 | Fox Jonathan C | Director | Grant | 473 | $0.00 | $0 | 24K |
| 2025-11-12 | Russell Alan J | Chief Scientific Officer | Sell | 100K | $21.12 | $2.1M | 23K |
| 2025-11-12 | Russell Alan J | Chief Scientific Officer | Exercise or conversion | 100K | $0.18 | $18K | 123K |
| 2025-11-11 | Fox Jonathan C | Director | Buy | 11K | $18.64 | $199K | 24K |
| 2025-10-01 | Fox Jonathan C | Director | Grant | 728 | $0.00 | $0 | 13K |
| 2025-08-26 | Russell Alan J | Chief Scientific Officer | Sell | 100K | $14.60 | $1.5M | 23K |
| 2025-08-26 | Russell Alan J | Chief Scientific Officer | Exercise or conversion | 100K | $0.18 | $18K | 123K |
| 2025-08-12 | MOORE JOHN R | General Counsel | Sell | 2K | $13.39 | $28K | 10K |
| 2025-08-12 | MOORE JOHN R | General Counsel | Exercise or conversion | 6K | $0.00 | $0 | 12K |
| 2025-08-12 | Russell Alan J | Chief Scientific Officer | Sell | 2K | $13.39 | $26K | 23K |
| 2025-08-12 | Russell Alan J | Chief Scientific Officer | Exercise or conversion | 6K | $0.00 | $0 | 25K |
| 2025-08-12 | KOCH KEVIN | President and CEO | Sell | 8K | $13.39 | $107K | 31K |
| 2025-08-12 | KOCH KEVIN | President and CEO | Exercise or conversion | 18K | $0.00 | $0 | 39K |
| 2025-08-12 | Donovan Joanne M. | CMO | Sell | 3K | $13.39 | $38K | 25K |
| 2025-08-12 | Donovan Joanne M. | CMO | Exercise or conversion | 6K | $0.00 | $0 | 28K |
| 2025-08-12 | Derakhshan Behrad | Chief Business Officer | Sell | 2K | $13.39 | $33K | 24K |
| 2025-08-12 | Derakhshan Behrad | Chief Business Officer | Exercise or conversion | 6K | $0.00 | $0 | 26K |
| 2025-08-12 | Carruthers R Michael | Chief Financial Officer | Sell | 1K | $13.39 | $19K | 86K |
| 2025-08-12 | Carruthers R Michael | Chief Financial Officer | Exercise or conversion | 6K | $0.00 | $0 | 88K |
| 2025-07-01 | Fox Jonathan C | Director | Grant | 858 | $0.00 | $0 | 12K |
| 2025-05-02 | Carruthers R Michael | Chief Financial Officer | Sell | 1K | $16.45 | $22K | 81K |
| 2025-05-02 | Derakhshan Behrad | Chief Business Officer | Sell | 2K | $16.45 | $28K | 20K |
| 2025-05-02 | Donovan Joanne M. | CMO | Sell | 5K | $16.45 | $85K | 22K |
| 2025-05-02 | KOCH KEVIN | President and CEO | Sell | 4K | $16.45 | $70K | 21K |
| 2025-05-02 | MOORE JOHN R | General Counsel | Sell | 2K | $16.45 | $32K | 7K |
| 2025-05-02 | Russell Alan J | Chief Scientific Officer | Sell | 2K | $16.45 | $26K | 19K |
| 2025-05-01 | Carruthers R Michael | Chief Financial Officer | Exercise or conversion | 5K | $0.00 | $0 | 82K |
| 2025-05-01 | Derakhshan Behrad | Chief Business Officer | Exercise or conversion | 5K | $0.00 | $0 | 22K |
| 2025-05-01 | Donovan Joanne M. | CMO | Exercise or conversion | 10K | $0.00 | $0 | 27K |
| 2025-05-01 | KOCH KEVIN | President and CEO | Exercise or conversion | 10K | $0.00 | $0 | 25K |
| 2025-05-01 | MOORE JOHN R | General Counsel | Exercise or conversion | 5K | $0.00 | $0 | 8K |
| 2025-05-01 | Russell Alan J | Chief Scientific Officer | Exercise or conversion | 5K | $0.00 | $0 | 20K |
| 2025-04-03 | OrbiMed Genesis GP LLC | Director,TenPercentOwner | Buy | 373K | $20.13 | $7.5M | 14.8M |
| 2025-04-03 | OrbiMed Genesis GP LLC | Director,TenPercentOwner | Buy | 124K | $20.13 | $2.5M | 444K |
| 2025-04-03 | Thompson Peter A. | Director,TenPercentOwner | Buy | 124K | $20.13 | $2.5M | 444K |
| 2025-04-03 | Thompson Peter A. | Director,TenPercentOwner | Buy | 373K | $20.13 | $7.5M | 14.8M |
| 2025-04-01 | Fox Jonathan C | Director | Grant | 559 | $0.00 | $0 | 11K |
| 2025-03-07 | KOCH KEVIN | President and CEO | Exercise or conversion | 100 | $0.18 | $18 | 15K |
| 2025-03-07 | KOCH KEVIN | President and CEO | Sell | 100 | $30.00 | $3K | 14K |
| 2025-03-07 | Russell Alan J | Chief Scientific Officer | Sell | 200 | $30.02 | $6K | 15K |
| 2025-03-07 | Russell Alan J | Chief Scientific Officer | Exercise or conversion | 200 | $0.18 | $36 | 15K |
| 2025-02-06 | KOCH KEVIN | President and CEO | Exercise or conversion | 900 | $13.11 | $12K | 15K |
| 2025-02-06 | KOCH KEVIN | President and CEO | Sell | 900 | $31.13 | $28K | 14K |
| 2025-02-06 | Russell Alan J | Chief Scientific Officer | Exercise or conversion | 1K | $0.18 | $216 | 16K |
| 2025-02-06 | Russell Alan J | Chief Scientific Officer | Sell | 1K | $30.13 | $36K | 15K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON10 Form 144 notices on file for EWTX worth $32.1M at the prices reported; 1 in the last 90 days worth $127K. Latest: JOANNE DONOVAN filed on 2026-08-13 to sell 2,919 shares ($127K) from 2026-08-13.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-08-13 | JOANNE DONOVANOfficer | 3K | $127K | 0.003% | 2026-08-13 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-07-01 | ALAN J RUSSELLDirector, Officer | 200K | $8.1M | 0.186% | 2026-07-01 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-05-05 | JOANNE DONOVANOfficer | 50K | $1.6M | 0.047% | 2026-05-05 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-27 | JOANNE DONOVANOfficer | 72K | $2.3M | 0.067% | 2026-03-27 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-01-21 | Badreddin EdrisDirector | 115K | $3.4M | 0.109% | 2026-01-21 | J.P. Morgan Securities LLC |
| 2026-01-20 | ROBERT MICHAEL CARRUTHERSOfficer | 184K | $5.2M | 0.174% | 2026-01-20 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-01-15 | ROBERT MICHAEL CARRUTHERSOfficer | 181K | $4.8M | 0.171% | 2026-01-15 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-12-29 | ROBERT MICHAEL CARRUTHERSOfficer | 117K | $3.0M | 0.110% | 2025-12-26 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-11-17 | ROBERT MICHAEL CARRUTHERSOfficer | 70K | $1.6M | 0.066% | 2025-11-17 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-11-12 | ALAN J RUSSELLOfficer, Director | 100K | $2.1M | 0.094% | 2025-11-12 | Morgan Stanley Smith Barney LLC Executive Financial Services |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON11 holders report 5% or more of EWTX in their latest filing, all on Schedule 13G (passive). The largest reported stake is Paradigm BioCapital Advisors LP at 9.5% of the class (10,215,455 shares), filed 2026-08-14 for an event on 2026-06-30.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-08-14 | 13G/Ano. 2 | RA Capital Healthcare Fund, L.P.partnership | 8.4M | 7.8% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | RA Capital Management, L.P.investment adviser, partnership | 8.4M | 7.8% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Peter Kolchinskyparent holding company, individual | 8.4M | 7.8% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Rajeev Shahparent holding company, individual | 8.4M | 7.8% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Paradigm BioCapital Advisors LPpartnership | 10.2M | 9.5% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Senai Asefaw, M.D.individual | 10.2M | 9.5% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Paradigm BioCapital Advisors GP LLCother entity | 10.2M | 9.5% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Paradigm BioCapital International Fund Ltd.corporation | 9.0M | 8.3% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Baker Bros. Advisors LPinvestment adviser, partnership | 3.7M | 3.4% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Felix J. Bakerparent holding company, individual | 3.7M | 3.4% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Julian C. Bakerparent holding company, individual | 3.7M | 3.4% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Baker Bros. Advisors (GP) LLCparent holding company, other entity | 3.7M | 3.4% | 2026-06-30 |
| 2026-08-06 | 13G | FMR LLCparent holding company | 5.5M | 5.1% | 2026-06-30 |
| 2026-08-06 | 13G | Abigail P. Johnsonindividual | 5.5M | 5.1% | 2026-06-30 |
| 2026-05-15 | 13G | JANUS HENDERSON GROUP PLCparent holding company | 5.9M | 5.5% | 2026-03-31 |
| 2026-04-27 | 13D/Ano. 6 | Novo Holdings A/Scorporation | 5.3M | 4.9% | 2026-04-23 |
13F holders
Tracked managers holding EWTX at their latest 13F. JSON5 of the 30 tracked managers held EWTX at their latest 13F, $34.3M in total at quarter-end prices. Citadel Advisors is the largest at $19.1M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 4 added shares and 1 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Citadel Advisors | 2026-06-30 | 470K | $19.1M | 0.00% | +41K |
| D. E. Shaw & Co. | 2026-06-30 | 189K | $7.7M | 0.00% | +84K |
| Point72 Asset Management | 2026-06-30 | 117K | $4.8M | 0.01% | new |
| Two Sigma Investments | 2026-06-30 | 50K | $2.0M | 0.00% | -1K |
| AQR Capital Management | 2026-06-30 | 18K | $750K | 0.00% | +10K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn FY 2025 it generated -$143.8M of operating cash flow.
- Cash
- $72.3M
- Equity
- $448.1M
- Total assets
- $479.7M
- Shares outstanding
- 108,604,129
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 FY 2026 | 2026-06-30 | n/a | -$57.3M | n/a | -0.53 |
| Q1 FY 2026 | 2026-03-31 | n/a | -$49.0M | n/a | -0.46 |
| Q4 FY 2025derived | 2025-12-31 | n/a | -$50.2M | n/a | n/a |
| Q3 FY 2025 | 2025-09-30 | n/a | -$40.7M | n/a | -0.39 |
| Q2 FY 2025 | 2025-06-30 | n/a | -$36.1M | n/a | -0.34 |
| Q1 FY 2025 | 2025-03-31 | n/a | -$40.8M | n/a | -0.43 |
| Q4 FY 2024derived | 2024-12-31 | n/a | -$39.7M | n/a | n/a |
| Q3 FY 2024 | 2024-09-30 | n/a | -$34.1M | n/a | -0.36 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | n/a | -$167.8M | -$143.8M | $256K | n/a | n/a |
| FY 2024 | 2024-12-31 | n/a | -$133.8M | -$109.0M | $1.3M | n/a | n/a |
| FY 2023 | 2023-12-31 | n/a | -$100.2M | -$91.9M | $5.7M | n/a | n/a |
| FY 2022 | 2022-12-31 | n/a | -$67.6M | -$52.6M | $5.5M | n/a | n/a |
| FY 2021 | 2021-12-31 | n/a | -$42.8M | -$33.5M | $668K | n/a | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-07-31 from the cover page.
What this page is
Edgewise Therapeutics in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Edgewise Therapeutics (EWTX), SEC CIK 1710072, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-09-09.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-08-13.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-08-14.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-06.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-10-01.JSON and CSV
- Company record
- EDGAR filing index for CIK 1710072Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
- STESTERIS
- STLDSteel Dynamics
- STRCStrategy
- STRLSterling Infrastructure
- STTState Street
- STXSeagate Technology Holdings
- STZConstellation Brands
- SUISun Communities
- SUNBSunbelt Rentals Holdings
- SWSmurfit Westrock
- SWKStanley Black & Decker
- SWKSSkyworks Solutions
- SXTCChina SXT Pharmaceuticals
- SYFSynchrony Financial
- SYKStryker
- SYNASynaptics
Datasets
Frequently Asked Questions
How much of EWTX is sold short?
11,751,785 shares were held short at the 2026-10-15 settlement, 8.5 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is EWTX's daily short volume?
On 2026-11-02, 197,866 of the 344,852 EWTX shares reported to FINRA were sold short, 57.4% of the day's reported volume. Short volume is a flow for one day, not a position.
Does EWTX have fails to deliver?
The SEC's latest file shows 226 EWTX shares failed to deliver at settlement 2026-09-09. Fails are reported per settlement date and published twice a month with a lag.
Are EWTX insiders buying or selling?
Insiders at EWTX reported 19 open-market sells worth $1.9M in the last 90 days and no open-market buys. Latest filing: Fox Jonathan C (Director) on 2026-10-01.
Have EWTX insiders filed to sell?
10 Form 144 notices on file for EWTX worth $32.1M at the prices reported; 1 in the last 90 days worth $127K. Latest: JOANNE DONOVAN filed on 2026-08-13 to sell 2,919 shares ($127K) from 2026-08-13.
Who owns 5% or more of EWTX?
11 holders report 5% or more of EWTX in their latest filing, all on Schedule 13G (passive). The largest reported stake is Paradigm BioCapital Advisors LP at 9.5% of the class (10,215,455 shares), filed 2026-08-14 for an event on 2026-06-30.
What did EWTX report last quarter?
In FY 2025 it generated -$143.8M of operating cash flow.
Which tracked 13F managers own EWTX?
5 of the 30 tracked 13F managers held EWTX shares at their latest filing, $34.3M in all. The largest: Ken Griffin's Citadel Advisors (470K shares, $19.1M), D. E. Shaw & Co. (189K shares, $7.7M), Steve Cohen's Point72 Asset Management (117K shares, $4.8M), Two Sigma Investments (50K shares, $2.0M), Cliff Asness's AQR Capital Management (18K shares, $750K).
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.